Compounds > 4-hydroxy-6-methyl-2-pyrone
Page last updated: 2024-08-03 18:17:32

4-hydroxy-6-methyl-2-pyrone

Description

4-hydroxy-6-methyl-2-pyrone: structure in first source [MeSH]

triacetate lactone : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID54675757
CHEMBL ID54907
SCHEMBL ID320025
SCHEMBL ID918518
CHEBI ID16458
MeSH IDM0516625

Synonyms (100)

Synonym
unii-s1s883s4ee
s1s883s4ee ,
BRD-K77202630-001-02-9
4-hydroxy-6-methyl-2h-pyran-2-one
CHEBI:16458 ,
2h-pyran-2-one, 4-hydroxy-6-methyl-
triacetic acid lactone
nsc34625
nsc-34625
DIVK1C_006912
SDCCGMLS-0066925.P001
SPECTRUM4_001907
SPECTRUM_001904
BSPBIO_003340
nsc 34625
6-methyl-4-hydroxypyron-(2)
einecs 211-619-2
4-hydroxy-6-methylpyran-4-one
brn 0113815
ccris 3600
SPECTRUM5_000594
675-10-5
4-hydroxy-6-methyl-2-pyrone
triacetate lactone
C02752
4-hydroxy-6-methyl-2-pyrone, 98%
NCGC00095976-01
KBIO2_005000
KBIO1_001856
KBIO2_007568
KBIOSS_002438
KBIO3_002560
KBIO2_002432
KBIOGR_002500
SPECPLUS_000816
SPBIO_002135
SPECTRUM2_001978
SPECTRUM3_001720
SPECTRUM1600759
NCGC00178130-01
inchi=1/c6h6o3/c1-4-2-5(7)3-6(8)9-4/h2-3,7h,1h
CHEMBL54907 ,
4-hydroxy-6-methylpyran-2-one
3,5-dihydroxysorbic acid delta-lactone
H0715
AKOS000119605
NCGC00095976-02
6-methyl-4-hydroxy-2-pyrone
2-hydroxy-6-methyl-4h-pyran-4-one
70254-61-4
AKOS016007260
CCG-39516
bdbm50405204
FT-0618665
4-hydroxy-6-methyl-.alpha.-pyrone
sorbic acid, 3,5-dihydroxy-, .delta.-lactone
SCHEMBL320025
7H-939
4-hydroxy-6-methylpyranone
4-hydroxy-6 -methyl-2-pyrone
6-methyl-4-hydroxy pyran-2-one
6-methyl-4-hydroxypyran-2-one
4-hydroxy-6-methyl-pyran-2-one
4-hydroxy-6-methyl-pyrone
6-methyl-4-hydroxypyrone
OOKCZXGEYPSNIM-UHFFFAOYSA-N
4-hydroxy-6-methyl pyranone
4- hydoxy-6-methyl-2-pyrone
4-hydroxy-6-methyl pyr-2-one
4-hydroxy-6-methylpyrone
4-hydroxy- 6-methyl-2-pyrone
4-hydoxy-6-methyl-2-pyrone
DTXSID1060974
SCHEMBL918518
W-104713
CS-W020045
AC-27196
mfcd00006641
F0001-1779
3,5-dihydroxysorbic acid d-lactone
4h-pyran-4-one, 2-hydroxy-6-methyl-
SR-05000002374-1
sr-05000002374
SY001948
F14831
mfcd18820248
FT-0715301
Q7839869
AMY23278
BRD-K77202630-001-03-7
O10801
CS-0061284
A866649
kj6 ,
6-methyl-4-oxidanyl-pyran-2-one
EN300-20217
PD000450
HY-Y1634
SY105730
Z104477314

Drug Classes (1)

ClassDescription
2-pyranonesA pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives.

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
alpha-galactosidaseHomo sapiens (human)Potency0.7943AID2107
DNA polymerase kappa isoform 1Homo sapiens (human)Potency35.4813AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.8107AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.8107AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.8107AID885

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chymotrypsin-like elastase family member 1Sus scrofa (pig)Ki3,090.3000AID156214
Neutrophil elastaseHomo sapiens (human)Ki8,128.3100AID66470
Chymotrypsin-CHomo sapiens (human)Ki6,309.5700AID52466

Bioassays (17)

Assay IDTitleYearJournalArticle
AID715795Induction of apoptosis in human U937 cells assessed as reduction of normal cells at 500 uM after 24 hrs by Annexin V-FITC double staining2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3391		Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
ISSN: 1521-0111		Structure-based identification of OATP1B1/3 inhibitors.
AID1101274Antifungal activity against Sclerotium delphinii assessed as fungal growth inhibition at 100 ppm relative to untreated control2001Bioscience, biotechnology, and biochemistry, Jan, Volume: 65, Issue:1
ISSN: 0916-8451		Syntheses and biological activities of pyranyl-substituted cinnamates.
AID1865413Inhibition of full length recombinant C-terminal FLAG-tagged human HDAC2 expressed in baculovirus-infected Sf9 cells at 1 mM measured for 2 hrs by fluorescence-based assay relative to control2022ACS medicinal chemistry letters, Oct-13, Volume: 13, Issue:10
ISSN: 1948-5875		Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.
AID1101273Antifungal activity against Rhizoctonia solani assessed as fungal growth inhibition at 100 ppm relative to untreated control2001Bioscience, biotechnology, and biochemistry, Jan, Volume: 65, Issue:1
ISSN: 0916-8451		Syntheses and biological activities of pyranyl-substituted cinnamates.
AID1754626Inhibition of Wnt signalling in HEK293 cells harbouring TCF/beta-catenin luciferase reporter gene assessed as TCF/beta-catenin transcriptional activity at 30 to 60 uM by TOPFlash luciferase assay2021Bioorganic & medicinal chemistry letters, 08-01, Volume: 45ISSN: 1464-3405Linderapyrone: A Wnt signal inhibitor isolated from Lindera umbellata.
AID715776Pro-oxidant activity in 0.1 M potassium phosphate buffer at pH 7.4 assessed as increase of oxidation potential by cyclic voltammetry analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3391		Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715803Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3391		Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715802Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3391		Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID715783Induction of cell differentiation in human U937 cells assessed as increase of CD11b and CD14 expression at 500 uM after 72 hrs by FACS flow cytometer analysis2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3391		Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action.
AID19471Partition coefficient (logP) (octanol/saline)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
ISSN: 0022-2623		Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID156214Inhibitory activity against porcine pancreatic elastase (PP elastase) expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
ISSN: 0022-2623		Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID52466Inhibitory activity against bovine Chymotrypsinogen expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
ISSN: 0022-2623		Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
ISSN: 1521-0111		Structure-based identification of OATP1B1/3 inhibitors.
AID66470Inhibitory activity against human leukocyte elastase (HL elastase) expressed as inhibitory constant1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
ISSN: 0022-2623		Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
ISSN: 1476-4679		6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
ISSN: 1552-454X		A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (8.70)18.7374
1990's2 (4.35)18.2507
2000's5 (10.87)29.6817
2010's21 (45.65)24.3611
2020's14 (30.43)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (95.65%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
6-pentylpyrone
0
2-pyranonesmetabolite00low000000
mevastatin
0
2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite		00low000000
2-pyrone
0
2-pyranones00low000000
7,8-dihydromethysticin
0
2-pyranones;
aromatic ether		00low000000
7,8-dihydro-5,6-dehydrokawain
0
2-pyranones;
aromatic ether		00low000000
ml 236a
0
2-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol		antiatherosclerotic agent;
anticholesteremic drug;
antilipemic drug;
antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite		00low000000
(+-)-Dihydromethysticin
0
2-pyranones;
aromatic ether		00low000000
parasorbic acid
0
2-pyranones00low000000
2,4-dimethyl-6-oxo-N-[(2,4,6-trifluorophenyl)methyl]-3-pyrancarboxamide
0
2-pyranones00low000000
5,6-dehydrokawain
0
2-pyranones;
aromatic ether		00low000000
kavain
0
2-pyranones;
aromatic ether		00low000000
methysticin
0
2-pyranones;
aromatic ether		00low000000
yangonin
0
2-pyranones;
aromatic ether		00low000000
citreoviridin
0
2-pyranones00low000000
fostriecin
0
2-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor		00low000000
monacolin j
0
2-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol		antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite		00low000000
7,8-Dihydroyangonin
0
2-pyranones;
aromatic ether		00low000000
dihydrokavain
0
2-pyranones;
aromatic ether		00low000000
obolactone
0
2-pyranones;
4-pyranones		antineoplastic agent;
plant metabolite		00low000000
phoslactomycin b
0
2-pyranones00low000000
dihydromonacolin l
0
2-pyranones;
octahydronaphthalenes		00low000000
monacolin l
0
2-pyranones;
hexahydronaphthalenes;
polyketide;
secondary alcohol		anticholesteremic drug;
Aspergillus metabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor		00low000000
kavain
0
2-pyranones;
aromatic ether		00low000000
hispidin
0
2-pyranones;
catechols		antioxidant;
EC 2.7.11.13 (protein kinase C) inhibitor;
fungal metabolite		00low000000
cryptocaryol a
0
2-pyranones;
pentol		plant metabolite00low000000
methysticin
0
2-pyranones;
aromatic ether		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
phenylacetic acid
1
benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin		202220222.0low000001
piperitone
1
cyclic terpene ketone;
p-menthane monoterpenoid		plant metabolite;
volatile oil component		202120213.0low000001
scoparone
1
aromatic ether;
coumarins		anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite		2012201212.0low000010
benzohydroxamic acid
1
202220222.0low000001
3-phenylbutyric acid
1
benzenes;
monocarboxylic acid		antibacterial agent;
bacterial xenobiotic metabolite		2012201212.0medium000010
2-pyrone
1
2-pyranones2012201212.0low000010
3-(3,4-dimethoxyphenyl)propanoic acid
1
dimethoxybenzene;
monocarboxylic acid		2012201212.0medium000010
7-amino-4-methylcoumarin
1
7-aminocoumarinsfluorochrome2012201212.0low000010
7,8-dihydro-5,6-dehydrokawain
1
2-pyranones;
aromatic ether		2001200123.0medium000100
3,4-dihydroxyphenylpropionic acid
1
(dihydroxyphenyl)propanoic acidantioxidant;
human xenobiotic metabolite		2012201212.0low000010
trans-4-coumaric acid
1
4-coumaric acidfood component;
mouse metabolite;
plant metabolite		2012201212.0low000010
caffeic acid
1
caffeic acidgeroprotector;
mouse metabolite		2012201212.0low000010
3-(3,4-dimethoxyphenyl)propenoic acid
1
methoxycinnamic acid2012201212.0low000010
fraxetin
1
aromatic ether;
hydroxycoumarin		anti-inflammatory agent;
antibacterial agent;
antimicrobial agent;
antioxidant;
apoptosis inducer;
apoptosis inhibitor;
Arabidopsis thaliana metabolite;
hepatoprotective agent;
hypoglycemic agent		2012201212.0low000010
5,6-dehydrokawain
1
2-pyranones;
aromatic ether		202120213.0low000001
scopoletin
1
hydroxycoumarinplant growth regulator;
plant metabolite		2012201212.0low000010
hymecromone
1
hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor		2012201212.0low000010
esculetin
1
hydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter		2012201212.0low000010
4-methylesculetin
1
hydroxycoumarinanti-inflammatory agent;
antioxidant;
hyaluronan synthesis inhibitor		2012201212.0low000010
5,7-dihydroxy-4-methylcoumarin
1
hydroxycoumarin2012201212.0low000010
7,8-dihydroxy-4-methylcoumarin
1
hydroxycoumarin2012201212.0low000010
7-hydroxy-4-methyl-1H-quinolin-2-one
1
hydroxyquinoline;
quinolone		2012201212.0medium000010
icg 001
1
peptide202120213.0low000001
iwr-1 endo
1
benzamides;
bridged compound;
dicarboximide;
quinolines		axin stabilizer;
Wnt signalling inhibitor		202120213.0low000001
elasnin
1
1985198539.0medium010000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetic acid
1
monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent		201520159.0low000010
acetone
1
ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent		1992199232.0low001000
phloroglucinol
2
benzenetriol;
phenolic donor		algal metabolite201620177.5low000020
glycerol
1
alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent		201520159.0low000010
4-aminopyridine
1
aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker		201720177.0low000010
serine
1
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2014201410.0low000010
methionine
1
aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical		201520159.0low000010
6-methylsalicylic acid
1
monohydroxybenzoic acidPenicillium metabolite;
plant metabolite		1992199232.0low001000
4-dimethylaminopyridine
1
dialkylarylamine;
tertiary amino compound		201720177.0low000010
palladium
1
metal allergen;
nickel group element atom;
platinum group metal atom		201520159.0low000010
alkenes
1
202020204.0low000010
orsellinic acid
1
dihydroxybenzoic acid;
resorcinols		fungal metabolite;
marine metabolite;
metabolite		202020204.0low000010
2-pyrone
4
2-pyranones201520236.0medium000031
1,3-dibromo-2-propanone
1
1992199232.0medium001000
coenzyme a
1
adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite		1981198143.0low010000
acetoacetyl coa
1
3-oxo-fatty acyl-CoAEscherichia coli metabolite;
mouse metabolite		1981198143.0low010000
xylose
2
D-xylose202020213.5low000011
hydroxyl radical
1
oxygen hydride;
oxygen radical;
reactive oxygen species		2004200420.0low000100
lignin
1
202120213.0low000001
alpha bitter acid
1
aromatic ketone;
cyclic ketone;
diketone;
tertiary alpha-hydroxy ketone;
triol		antibacterial drug;
antioxidant;
cyclooxygenase 2 inhibitor;
metabolite		201620168.0low000010
acetyl coenzyme a
6
acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite		1981202220.7low021012
3-hydroxy-3-methylglutaryl-coenzyme a
1
3-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA		human metabolite;
mouse metabolite		201520159.0low000010
retinol
1
retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite		202120213.0low000001
riboflavin
1
flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite		202020204.0low000010
glycosides
1
202020204.0low000010
3-hydroxybutyryl-coenzyme a
1
3-hydroxyacyl-CoA;
hydroxybutanoyl-CoA		mouse metabolite1981198143.0low010000
malonyl coenzyme a
3
malonyl-CoAsEC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite		1981201726.0low011010
sesquiterpenes
1
1996199628.0low001000
nadp
2
1981199635.5low011000
alpha-chymotrypsin
1
201520159.0low000010
alpha-linolenic acid
1
linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical		202020204.0low000010
sulfur
1
chalcogen;
nonmetal atom		macronutrient201520159.0low000010
4-coumaroyl-coenzyme a
1
4-coumaroyl-CoA202020204.0low000010
aluminum oxide
1
201520159.0low000010
nad
1
organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite		1981198143.0low010000
piperidines
1
202120213.0low000001
salicylates
1
monohydroxybenzoateplant metabolite1992199232.0low001000
pogostone
1
aromatic ketone201720177.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acetonemia0
1
201520159.0medium000010
Anemia, Fanconi0
1
201620168.0medium000010
Benign Neoplasms0
1
201520159.0medium000010
Fanconi Anemia0
1
201620168.0medium000010
Fasting Hypoglycemia0
1
201520159.0medium000010
Hypoglycemia0
1
201520159.0medium000010
Neoplasms0
1
201520159.0medium000010
Pregnancy0
1
1981198143.0medium010000
Sensitivity and Specificity0
1
202020204.0medium000010

Bioavailability (1)

ArticleYear
In vitro bactericidal activity of 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrone (CHP) against drug-susceptible, drug-resistant and drug-tolerant isolates of Mycobacterium tuberculosis.
Journal of global antimicrobial resistance, , Volume: 22		2020